#NAME?
Hepion Pharmaceuticals Schedules Conference Call
EDISON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (œAI)-driven therapeutic...
- 850 cancer cell lines screened in Broad Institute™s PRISM lab - - Rencofilstat active on 220 cancer cell lines spanning 86% of cancer types “ EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) --...
“ Proteomics analysis showed that rencofilstat improved aberrant protein profiles in IPF tissues “ “ Superior effects of rencofilstat alone and in combination with pirfenidone and...
EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH Congress
Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors
EDISON, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...